compani
trim ep boost
addit loxo
ep loxo modestli boost out-yr
ep result modestli miss our/street est
guidanc reflect loxo acquisit lartruvo miss combin
drag lower ep remain broadli unchang
increas reflect addit loxo product ep
y/i slightli mid-point guidanc inclus
drag y/i sale ciali loe loss lartruvo growth outlook
cleaner driven lli new product cycl forecast still includ elanco
updat upon complet exchang offer reiter neutral
rate given limit catalyst drive re-rat rel lli premium multipl
takeaway confer call
notabl updat drug price us price declin across portfolio
expect mid-singl digit decreas includ point medicar
donut hole expans point drag subsid patient key product
new launch taltz trulic emgal remaind mix unit
declin olumi ad three dose trial hit
primari endpoint intend present detail data medic meet three
addit studi readout emgal remain bullish
outlook emgal given favor uptak trajectori new start ytd expans
primari care broad formulari access management note paid prescript ratio similar
amgen comment price discount vs competitor
verzenio view label expans market share gain geograph expans
driver verzenio given plateau penetr us market inventori
impact thu repres small fraction product miss
jardianc management see tailwind product come better
formulari access re-inclus formulari prefer treatment list
treatment guidelin categori growth oncolog
immunolog remain two key area focu continu page
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
loe loss exclus
ret rearrang transfect
timestamp februari estcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani februari
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough target
ad loxo model
model includ two asset loxo deal expect close
end vitrakvi profit share bayer approv nov vitrakvi
target cancer ntrk fusion protein use bofaml eu pharma team forecast
bayer deriv peak sale asset
target cancer ret mutat estim risk-adjust peak sale
probabl success assum list price durat
treatment deduct share global ret-mut patient
compani februari
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani februari
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani februari
